The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Mental Disorders Drugs-Global Market Insights and Sales Trends 2025
Synopsis
The global Mental Disorders Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Mental Disorders Drugs in various end use industries. The expanding demands from the Children, Adolescents and Adults,, are propelling Mental Disorders Drugs market. Drugs for Schizophrenia, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antidepressants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Mental Disorders Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Mental Disorders Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Mental Disorders Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Mental Disorders Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Mental Disorders Drugs covered in this report include Johnson & Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and Abbott Laboratories, etc.
The global Mental Disorders Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Johnson & Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Abbott Laboratories
Global Mental Disorders Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Mental Disorders Drugs market, Segment by Type:
Drugs for Schizophrenia
Antidepressants
Antipsychotics
Anxiolytics
Drugs for the Treatment of Substance and Alcohol Addiction
Drugs for Childhood and Adolescent Mental Illness
Drugs to Treat Cognitive Disorders
Sleep Disorders
Others
Global Mental Disorders Drugs market, by Application
Children
Adolescents
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Mental Disorders Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Mental Disorders Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Mental Disorders Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Mental Disorders Drugs in various end use industries. The expanding demands from the Children, Adolescents and Adults,, are propelling Mental Disorders Drugs market. Drugs for Schizophrenia, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antidepressants segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Mental Disorders Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Mental Disorders Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Mental Disorders Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Mental Disorders Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Mental Disorders Drugs covered in this report include Johnson & Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and Abbott Laboratories, etc.
The global Mental Disorders Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Johnson & Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Abbott Laboratories
Global Mental Disorders Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Mental Disorders Drugs market, Segment by Type:
Drugs for Schizophrenia
Antidepressants
Antipsychotics
Anxiolytics
Drugs for the Treatment of Substance and Alcohol Addiction
Drugs for Childhood and Adolescent Mental Illness
Drugs to Treat Cognitive Disorders
Sleep Disorders
Others
Global Mental Disorders Drugs market, by Application
Children
Adolescents
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Mental Disorders Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Mental Disorders Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Mental Disorders Drugs Market Overview
1.1 Mental Disorders Drugs Product Overview
1.2 Mental Disorders Drugs Market Segment by Type
1.2.1 Drugs for Schizophrenia
1.2.2 Antidepressants
1.2.3 Antipsychotics
1.2.4 Anxiolytics
1.2.5 Drugs for the Treatment of Substance and Alcohol Addiction
1.2.6 Drugs for Childhood and Adolescent Mental Illness
1.2.7 Drugs to Treat Cognitive Disorders
1.2.8 Sleep Disorders
1.2.9 Others
1.3 Global Mental Disorders Drugs Market Size by Type
1.3.1 Global Mental Disorders Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Mental Disorders Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Mental Disorders Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Mental Disorders Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Mental Disorders Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Mental Disorders Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Mental Disorders Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Mental Disorders Drugs Sales Breakdown by Type (2018-2023)
2 Global Mental Disorders Drugs Market Competition by Company
2.1 Global Top Players by Mental Disorders Drugs Sales (2018-2023)
2.2 Global Top Players by Mental Disorders Drugs Revenue (2018-2023)
2.3 Global Top Players by Mental Disorders Drugs Price (2018-2023)
2.4 Global Top Manufacturers Mental Disorders Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Mental Disorders Drugs Market Competitive Situation and Trends
2.5.1 Mental Disorders Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Mental Disorders Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mental Disorders Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Mental Disorders Drugs Market
2.8 Key Manufacturers Mental Disorders Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Mental Disorders Drugs Status and Outlook by Region
3.1 Global Mental Disorders Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Mental Disorders Drugs Historic Market Size by Region
3.2.1 Global Mental Disorders Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Mental Disorders Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Mental Disorders Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Mental Disorders Drugs Forecasted Market Size by Region
3.3.1 Global Mental Disorders Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Mental Disorders Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Mental Disorders Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Mental Disorders Drugs by Application
4.1 Mental Disorders Drugs Market Segment by Application
4.1.1 Children
4.1.2 Adolescents
4.1.3 Adults
4.2 Global Mental Disorders Drugs Market Size by Application
4.2.1 Global Mental Disorders Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Mental Disorders Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Mental Disorders Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Mental Disorders Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Mental Disorders Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Mental Disorders Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Mental Disorders Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Mental Disorders Drugs Sales Breakdown by Application (2018-2023)
5 North America Mental Disorders Drugs by Country
5.1 North America Mental Disorders Drugs Historic Market Size by Country
5.1.1 North America Mental Disorders Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Mental Disorders Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Mental Disorders Drugs Sales in Value by Country (2018-2023)
5.2 North America Mental Disorders Drugs Forecasted Market Size by Country
5.2.1 North America Mental Disorders Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Mental Disorders Drugs Sales in Value by Country (2024-2029)
6 Europe Mental Disorders Drugs by Country
6.1 Europe Mental Disorders Drugs Historic Market Size by Country
6.1.1 Europe Mental Disorders Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Mental Disorders Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Mental Disorders Drugs Sales in Value by Country (2018-2023)
6.2 Europe Mental Disorders Drugs Forecasted Market Size by Country
6.2.1 Europe Mental Disorders Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Mental Disorders Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Mental Disorders Drugs by Region
7.1 Asia-Pacific Mental Disorders Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Mental Disorders Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Mental Disorders Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Mental Disorders Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Mental Disorders Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Mental Disorders Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Mental Disorders Drugs Sales in Value by Region (2024-2029)
8 Latin America Mental Disorders Drugs by Country
8.1 Latin America Mental Disorders Drugs Historic Market Size by Country
8.1.1 Latin America Mental Disorders Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Mental Disorders Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Mental Disorders Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Mental Disorders Drugs Forecasted Market Size by Country
8.2.1 Latin America Mental Disorders Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Mental Disorders Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Mental Disorders Drugs by Country
9.1 Middle East and Africa Mental Disorders Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Mental Disorders Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Mental Disorders Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Mental Disorders Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Mental Disorders Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Mental Disorders Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Mental Disorders Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Johnson & Johnson
10.1.1 Johnson & Johnson Company Information
10.1.2 Johnson & Johnson Introduction and Business Overview
10.1.3 Johnson & Johnson Mental Disorders Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Johnson & Johnson Mental Disorders Drugs Products Offered
10.1.5 Johnson & Johnson Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Mental Disorders Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Pfizer Mental Disorders Drugs Products Offered
10.2.5 Pfizer Recent Development
10.3 Eli Lilly
10.3.1 Eli Lilly Company Information
10.3.2 Eli Lilly Introduction and Business Overview
10.3.3 Eli Lilly Mental Disorders Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Eli Lilly Mental Disorders Drugs Products Offered
10.3.5 Eli Lilly Recent Development
10.4 GlaxoSmithKline
10.4.1 GlaxoSmithKline Company Information
10.4.2 GlaxoSmithKline Introduction and Business Overview
10.4.3 GlaxoSmithKline Mental Disorders Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 GlaxoSmithKline Mental Disorders Drugs Products Offered
10.4.5 GlaxoSmithKline Recent Development
10.5 AstraZeneca
10.5.1 AstraZeneca Company Information
10.5.2 AstraZeneca Introduction and Business Overview
10.5.3 AstraZeneca Mental Disorders Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 AstraZeneca Mental Disorders Drugs Products Offered
10.5.5 AstraZeneca Recent Development
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Company Information
10.6.2 Bristol-Myers Squibb Introduction and Business Overview
10.6.3 Bristol-Myers Squibb Mental Disorders Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Bristol-Myers Squibb Mental Disorders Drugs Products Offered
10.6.5 Bristol-Myers Squibb Recent Development
10.7 Abbott Laboratories
10.7.1 Abbott Laboratories Company Information
10.7.2 Abbott Laboratories Introduction and Business Overview
10.7.3 Abbott Laboratories Mental Disorders Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Abbott Laboratories Mental Disorders Drugs Products Offered
10.7.5 Abbott Laboratories Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Mental Disorders Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Mental Disorders Drugs Industrial Chain Analysis
11.4 Mental Disorders Drugs Market Dynamics
11.4.1 Mental Disorders Drugs Industry Trends
11.4.2 Mental Disorders Drugs Market Drivers
11.4.3 Mental Disorders Drugs Market Challenges
11.4.4 Mental Disorders Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Mental Disorders Drugs Distributors
12.3 Mental Disorders Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
